Takeda Pharma, The Current Fiscal Year Net Income Revised Upward by 74%

About Information Provided on This Site

The information provided on our website 'Kabutan.com' is not intended to constitute investment solicitation or investment advisory services.
All investment decisions should be made at your own discretion and judgment.
The data on our website is provided by Tokyo Stock Exchange, Osaka Exchange, Nagoya Securities Exchange, JPX Market Innovation & Research, Japannext, and other sources.
Copyright of the Nikkei Stock Average belongs to Nikkei Inc. Stock price charts displayed on Kabutan.com are provided solely for the purpose of reviewing historical price movements of the securities.
These charts neither suggest nor guarantee future price movements of the securities and do not constitute recommendations to buy or sell.
In our financial results coverage, the term 'Surprise Results' identifies securities that demonstrate a significant degree of surprise in their earnings announcements.
This significance is quantitatively assessed based on multiple factors, including: the nature of the announcement (full-year or quarterly results); types of revisions (earnings or dividend forecasts); and numerical analysis comparing the announced results with both the company's previous forecasts and historical performance.
The 'Surprise Ranking' presents these results in order of their calculated surprise factor. Please note that neither these results nor rankings are intended to suggest or guarantee future performance of the listed securities, nor should they be construed as recommendations to buy or sell.

Thu Jan 30, 2025 3:30 pm JST Earnings

4502 Takeda Pharmaceutical Company Limited 【IFRS】

Earnings Report

Takeda Pharmaceutical Company Limited <4502> [TSE Prime] announced its financial results (based on IFRS) after the market closed on January 30th (15:30). The consolidated net income for the cumulative third quarter of the fiscal year ending March 2025 (April to December) expanded 211 billion yen, an increase 43.5% compared to the same period last year.

In addition, the full-year consolidated net income has been revised upward 73.5%, from the previous forecast of 68 billion yen to 118 billion yen (compared to 144 billion yen in the previous period), and the declining rate is expected to decrease from 52.8% to 18.1%.

Based on the full-year plan announced by the company after the upward revision, our estimate of the consolidated net income/loss for the October to March period (2H) has been revised upward from an expected loss of 119 billion yen to a loss of 69.2 billion yen (compared to a profit of 102 billion yen in the same period of the previous year), indicating a reduction in the loss margin.

In the most recent three-month period, from October to December (3Q), the consolidated net income significantly dropped to 23.7 billion yen, a 77.5% decrease compared to the same period last year. The operating profit margin drastically worsened from 9.4% in the same period last year to 5.9%.

Kabutan News

Actual Results

Accumulated Results 3rd Quarter

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Progress Rate vs. First Half	Announce	Accounting Standards
Apr - Dec, 2022	3,071,322	401,943	327,175	285,883	184.3	87.2	Feb 2, 2023	IFRS
Apr - Dec, 2023	3,212,893	224,144	100,313	147,085	94.1	190.0	Feb 1, 2024	IFRS
Apr - Dec, 2024	3,528,152	417,518	282,383	211,083	133.7	174.3	Jan 30, 2025	IFRS
YoY	+9.8%	+86.3%	+181.5%	+43.5%	+42.1%

Guidance Update

Second Half Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2024 Prev	2,095,972	-85,576	-162,976	-119,294	-75.6	98	Oct 31, 2024	IFRS
Oct - Mar, 2024 New	2,205,972	-6,576	-93,976	-69,294	-43.9	98	Jan 30, 2025	IFRS
Revision Rate	+5.2%	+92.3%	+42.3%	+41.9%	+41.9%

Full Year Update

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2025 Prev	4,480,000	265,000	93,000	68,000	43.1	196	Oct 31, 2024	IFRS
Mar, 2025 New	4,590,000	344,000	162,000	118,000	74.8	196	Jan 30, 2025	IFRS
Revision Rate	+2.5%	+29.8%	+74.2%	+73.5%	+73.5%

Current Period Guidance

Second Half Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Oct - Mar, 2023	2,162,055	94,845	13,738	102,702	65.7	94	May 9, 2024	IFRS
Oct - Mar, 2024 Guidance	2,205,972	-6,576	-93,976	-69,294	-43.9	98	Jan 30, 2025	IFRS
YoY	+2.0%	－	－	－	－

Current Period Guidance

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Adj. Dividend	Announce	Accounting Standards
Mar, 2023	4,027,478	490,505	375,090	317,017	204.3	180	May 11, 2023	IFRS
Mar, 2024	4,263,762	214,075	52,791	144,067	92.1	188	May 9, 2024	IFRS
Mar, 2025 Guidance	4,590,000	344,000	162,000	118,000	74.8	196	Jan 30, 2025	IFRS
YoY	+7.7%	+60.7%	+206.9%	-18.1%	-18.8%

Quarterly Results

Fiscal Year	Revenue	Operating Profit	Ordinary Profit	Net Profit	Adj. EPS	Operating Profit Margin	Announce	Accounting Standards
Oct - Dec, 2023	1,111,186	104,914	61,260	105,720	67.6	9.4	Feb 1, 2024	IFRS
Jan - Mar, 2024	1,050,869	-10,069	-47,522	-3,018	-1.9	-1.0	May 9, 2024	IFRS
Apr - Jun, 2024	1,207,990	166,329	136,604	95,248	60.7	13.8	Jul 31, 2024	IFRS
Jul - Sep, 2024	1,176,038	184,247	119,372	92,046	58.4	15.7	Oct 31, 2024	IFRS
Oct - Dec, 2024	1,144,124	66,942	26,407	23,789	15.1	5.9	Jan 30, 2025	IFRS
YoY	+3.0%	-36.2%	-56.9%	-77.5%	-77.7%